Home
Latest
Finance
IPO
ETF
Tech
Overseas
Video
Research
Topic
Download App
简
繁
简
繁
EN
Home
Latest
Finance
IPO
ETF
Tech
Overseas
Video
Research
Topic
HOME
·
Clinical Trial
HENLIUS(02696.HK): Bispecific EGFR/c-MET ADC HLX48 Doses First Patient
Tags:
HENLIUS
02696.HK
Clinical Trial
2026-06-30
REGENT PACIFIC(00575.HK): Deep Longevity Blood Biological Age Model Proven to Predict Mortality and Hospitalisation Risks in Research
Tags:
REGENT PACIFIC
00575.HK
Clinical Trial
2026-06-30
SINO BIOPHARM(01177.HK): Class 1 Innovative Drug Pelecanam Spray (Puyike®) Approved by NMPA for Secondary Wound Infection Caused by Burns and Scalds
Tags:
SINO BIOPHARM
01177.HK
Clinical Trial
2026-06-23
SIHUAN PHARM(00460.HK): First Patient Dosed in Phase III Trial of Anaprazole Sodium from Xuanzhu Biologics for Helicobacter Pylori Eradication
Tags:
SIHUAN PHARM
00460.HK
Clinical Trial
2026-06-22
INNOGEN-B(02591.HK): Ib-stage Clinical Trial of Efsubaglutide Alfa for Adolescent Obesity Approved, Expected to Kick Off in July
Tags:
INNOGEN-B
02591.HK
Clinical Trial
2026-06-22
Henlius(02696.HK):Phase 2 Clinical Trial of HLX43 Combined with Serplulimab for Neoadjuvant Treatment of NSCLC Approved in Australia
Tags:
HENLIUS
02696.HK
HLX43
Clinical Trial
2026-06-16
HENLIUS(02696.HK): HLX04-O Meets Primary Endpoint in Global Multicenter Phase 3 Trial for Wet Age-Related Macular Degeneration
Tags:
HENLIUS
02696.HK
Clinical Trial
2026-06-16
LongBio Pharma-B(01779.HK): LP-003 Phase III Trial for Seasonal Allergic Rhinitis Hits Primary Endpoint
Tags:
LongBio Pharma-B
01779.HK
Clinical Trial
2026-06-12
UNITED LAB(03933.HK): TUL321 Capsule Granted Implied Approval for Clinical Trials of New Drug in China
Tags:
UNITED LAB
03933.HK
Clinical Trial
2026-06-11
CSPC PHARMA(01093.HK): Phase III Study of Anistolimab Combined with HB1801 for HER2-positive Advanced Breast Cancer Meets Primary Endpoint
Tags:
CSPC PHARMA
01093.HK
Clinical Trial
2026-06-10
HBM HOLDINGS-B (02142.HK): NMPA Accepts IND Application of HBM7004 for Advanced Solid Tumors
Tags:
HBM HOLDINGS-B
02142.HK
Clinical Trial
2026-06-10
Leads Biolabs-B (09887.HK): Core Bispecific Antibody Initiates Phase Ib/II Trial for Triple-Negative Breast Cancer
Tags:
LEADS BIOLABS-B
09887.HK
Clinical Trial
2026-02-10
Previous
1
2
3
4
5
Finance
METIS TECHBIO-P (07666.HK): plans H-share buyback of up to HKD 300m
Finance
HENGRUI PHARMA (01276.HK): hetrombopag NDA accepted in China
Research
HK Stock Connect Daily: NETEASE -17.60% on Gaming Slump - 20261120
Finance
WATER OASIS GP (01161.HK): FY profit seen doubling to HKD 165-175m
Research
HK AI Concept Stock Daily: BABA-W +3.48% Defies Slump - 20261120
Research
Hong Kong Recently Listed Stocks Daily Report: BRAINAURORA-B Rises 39.50% to Lead; Intelligent Driving and Smart Parking Gain Traction-20261120
Finance
NewTimeSpace | HK Close: HSI -1.89%, Semis and Hardware Lead Declines
Research
HK shares ETFs Daily Report: Fubon Taiwan Semiconductor ETF Falls 9.81% as CSI 300 and India Themes Rise-Nov 20, 2026
Research
Offshore Trust Insight | NIO-SW (09866.HK) -5.07%; Users Trust 50m
Research
HK Stock Connect Insight | RA MATERIALS (09607.HK) -13.26%; Stake Rise
Scan QR Code
Download App